Test a VEGFR2 drug for sarcoma with lung lesions
Part of Cancer clinical trials.
This Phase 2 study tests a VEGFR2-targeted medicine in people with advanced or metastatic sarcoma whose cancer cannot be fully removed by surgery. It focuses on participants who have lung (pulmonary) lesions and whose prior standard chemotherapy did not work, to see if the biomarker-driven approach can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 8 to 65
- You have advanced or metastatic bone or soft-tissue sarcoma confirmed by biopsy, not a fatty tumor
- You must have lung lesions that doctors can see on scans
- Your cancer did not respond to standard first chemotherapy (based on NCCN guidelines)
- You are able to do most daily activities (ECOG 0–2) and are expected to live more than 3 months
- Your kidneys, liver, and blood counts are in acceptable ranges; blood pressure is normal or controlled
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a combination treatment for locally advanced or metastatic sarcoma that cannot be fully removed by surgery. It aims to shrink tumors and control disease by combining an injected cancer-killing medicine with two cancer-fighting drugs.
This trial tests a combination of two drugs, liposomal irinotecan and apatinib, for people with extensive-stage small cell lung cancer (ES-SCLC) that has progressed after first or second line treatment. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
This study tests whether the combination of two drugs, apatinib (a targeted therapy) and liposomal irinotecan (a chemotherapy), can help people with osteosarcoma that has not responded to standard treatments or has spread. The goal is to see if the combination can shrink tumors or slow the disease.
This study tests an experimental drug called VVD-159642 in people with advanced solid tumors that have specific genetic changes (RAS or EGFR alterations, or HER2 overexpression). The goal is to see if the drug is safe and tolerable.
This Phase 3 study tests two anti-cancer medicines (anlotinib and catequentinib) for people with certain advanced soft-tissue sarcomas, including alveolar soft part sarcoma, synovial sarcoma, and leiomyosarcoma. It is designed for tumors that cannot be removed and that have either grown despite treatment or no longer respond to standard options.
This Phase 2 trial tests pazopanib alone or together with pembrolizumab to slow or shrink metastatic soft-tissue sarcoma after prior chemotherapy. It may help some people by strengthening the anti-cancer effect compared with pazopanib by itself.
Hear when a new Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.